Community Prevalence of SARS-CoV-2 Among Patients With Influenzalike Illnesses Presenting to a Los Angeles Medical Center in March 2020

Abstract

Until recently, diagnostic testing for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), was only available through public health laboratories. [1][2][3] This limited testing was prioritized for persons who had severe illness or identifiable risk factors, such as travel to an area with ongoing transmission. Thus,

Epidemiology, Clinical Characteristics, And Treatment Outcomes Of Patients With COVID-19 At Siriraj Hospital – Thailand’s Largest University-Based Super-Tertiary Referral Center

“…No COVID-19 patient was documented among those without risk factors for COVID-19 acquisition. This nding is different from the epidemiologic reports from other countries where the outbreak situation of SARS-CoV-2 is ongoing [14]. The very low prevalence of COVID-19 among patients without risk factors for disease acquisition is also good supporting evidence for effective control of disease outbreak in Thailand.…”

Clinical features, diagnostics, and outcomes of patients presenting with acute respiratory illness: a comparison of patients with and without COVID-19

“…It is notable, however, that 44% of COVID-19 negative patients reported fevers and systemic symptoms were common. In contrast to other reports, [15][16][17][18][20][21][22][23] Further investigation of co-infections in COVID-19 positive patients, and assessment of their potential impact on disease severity and outcomes is needed, especially if SARS-CoV-2 circulation extends to overlap with other highly prevalent seasonal respiratory pathogens.…”

Face masks for the public during the covid-19 crisis

“…Individuals have been shown to be infectious up to 2.5 days before symptom onset,20 and as many as 50% of infections seem to occur from presymptomatic individuals 21. Community prevalence of covid-19 in many countries is likely to be high 22. Modelling studies suggest that even a small reduction in community transmission could make a major difference to demand elsewhere in the system (eg, for hospital bed space and ventilators) 23…”